{"organizations": [], "uuid": "373045ec1fa1d305ed88c26cceb6e3f7e2b92ca2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-astellas-says-cytomegalovirus-vacc/brief-astellas-says-cytomegalovirus-vaccine-did-not-meet-its-primary-or-secondary-endpoints-in-phase-3-helios-clinical-trial-idUSASB0C1N1", "country": "US", "domain_rank": 408, "title": "BRIEF-Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T10:13:00.000+02:00", "replies_count": 0, "uuid": "373045ec1fa1d305ed88c26cceb6e3f7e2b92ca2"}, "author": "", "url": "https://www.reuters.com/article/brief-astellas-says-cytomegalovirus-vacc/brief-astellas-says-cytomegalovirus-vaccine-did-not-meet-its-primary-or-secondary-endpoints-in-phase-3-helios-clinical-trial-idUSASB0C1N1", "ord_in_thread": 0, "title": "BRIEF-Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​", "locations": [], "entities": {"persons": [{"name": "mee", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "helios clinical trial​ reuters", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}, {"name": "vical", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News  15 AM / in 5 minutes BRIEF-Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​ Reuters Staff 1 Min Read \nJan 22 (Reuters) - Astellas Pharma Inc: \n* ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS \n* ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​ \n* ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T10:13:00.000+02:00", "crawled": "2018-01-22T10:24:31.019+02:00", "highlightTitle": ""}